A new biomarker in severe pneumonia associated with coronavirus disease 2019: hypoalbuminemia. A prospective study

Sao Paulo Med J. 2022 May-Jun;140(3):378-383. doi: 10.1590/1516-3180.2021.0066.R2.16082021.

Abstract

Background: Effective triage and early detection are very important for controlling and treating coronavirus disease 2019 (COVID-19). Thus, the relationships between hypoalbuminemia and other acute-phase reactants in such cases need to be evaluated.

Objectives: To investigate the importance of albumin levels in cases of severe pneumonia due to COVID-19.

Design and setting: Prospective study conducted in Ankara City Hospital (a stage 3 hospital), Turkey.

Methods: Data from 122 patients diagnosed with pneumonia due to COVID-19 who were admitted to this hospital were analyzed statistically in comparison with date from 60 healthy controls. Three groups were established: healthy controls, intubated patients and non-intubated patients. Lung tomography scans from the patients were examined one-by-one. Real-time polymerase chain reaction (RT-PCR) test results were recorded.

Results: Albumin levels were statistically significantly lower in the intubated and non-intubated groups than in the control group, in comparing the three groups (P < 0.01). The other acute-phase reactants, i.e. neutrophil-to-lymphocyte ratio and C-reactive protein levels, were significantly higher in the intubated and non-intubated groups than in the control group (P < 0.05). Albumin levels were also significantly lower in the intubated group than in the non-intubated group (P = 0.02). No differences were detected with regard to other parameters (P > 0.05).

Conclusions: Hypoalbuminemia may constitute a biomarker indicating the severity of pneumonia due to COVID-19.

MeSH terms

  • Acute-Phase Proteins
  • Albumins
  • Biomarkers
  • COVID-19* / complications
  • Humans
  • Hypoalbuminemia*
  • Prospective Studies
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • Acute-Phase Proteins
  • Albumins
  • Biomarkers